Specialties – Page 38

Long-Acting Injectable ART Superior to Oral Regimens in Patients with HIV Adherence Challenges: Insights from the LATITUDE Trial

By MedXY 02/22/2026

The LATITUDE trial reveals that monthly injectable cabotegravir-rilpivirine significantly reduces treatment failure compared to standard oral ART in individuals with HIV who struggle with daily medication adherence, potentially reshaping clinical guidelines for vulnerable patient populations.

Cardiology news

TAVR vs. Surgery in Low-Risk Patients: 7-Year PARTNER 3 Results Confirm Long-Term Parity

By MedXY 02/22/2026

Seven-year data from the PARTNER 3 trial demonstrate that TAVR remains noninferior to surgical aortic-valve replacement in low-risk patients, with comparable rates of death, stroke, and valve durability, supporting TAVR as a sustained alternative to surgery in this population.

Hematology-Oncology Nephrology news

Breaking the Cystine Barrier: Long-term Safety and Efficacy of CTNS-RD-04 Gene Therapy in Cystinosis

By MedXY 02/22/2026

A phase 1-2 trial shows that autologous hematopoietic stem-cell gene therapy (CTNS-RD-04) safely reduces lysosomal cystine levels in patients with cystinosis, potentially offering a definitive alternative to lifelong cysteamine therapy.

Neurology news

Delpacibart Etedesiran Shows Promise in Addressing the Molecular Root of Myotonic Dystrophy Type 1

By MedXY 02/22/2026

This phase 1-2 trial demonstrates that delpacibart etedesiran (del-desiran), an innovative antibody-oligonucleotide conjugate, effectively reduces toxic DMPK mRNA and ameliorates missplicing in patients with Myotonic Dystrophy Type 1, marking a potential breakthrough for a disease with no current approved therapies.

AI news Ophthalmology

Human-AI Collaboration Enhances Clinical Reasoning in Ophthalmology but Risks Overconfidence and Automation Bias

By MedXY 02/22/2026

A crossover study involving 30 ophthalmologists and trainees reveals that while Claude-3.5-Sonnet collaboration improves diagnostic accuracy in complex cases, it also increases confidence in incorrect decisions and fails to reach the performance of the AI alone.

Cardiology news Radiology

Beyond Stenosis: Why Quantitative Plaque Volume Is the New Frontier in Cardiovascular Risk Assessment

By MedXY 02/22/2026

A substudy of the PROMISE trial demonstrates that quantitative plaque measures on CCTA—specifically total and noncalcified plaque burden—independently predict major adverse cardiovascular events in symptomatic outpatients, offering a precision medicine approach beyond traditional clinical risk scores.

Emergency Medicine news Psychiatry

Injectable vs. Sublingual Buprenorphine: Shaping the Future of Emergency OUD Care

By MedXY 02/22/2026

The ED INNOVATION trial reveals that 7-day extended-release injectable buprenorphine is safe and as effective as sublingual formulations for treatment engagement, offering significant benefits in craving reduction and patient satisfaction even in fentanyl-prevalent environments.

Allergy & Immunology Dermatology news

Bridging the Gap: A New Evidence-Based Patient Decision Aid for Systemic Atopic Dermatitis Therapy

By MedXY 02/22/2026

Researchers have developed the first Patient Decision Aid (PDA) specifically for adult systemic atopic dermatitis treatments. The study highlights a 'staged approach' that balances clinician-driven data requirements with patient-preferred simplicity to enhance shared decision-making in clinical practice.

Gastroenterology General Surgery news

Beyond MELD: The Liver Immune Frailty Index (LIFI) Predicts Post-Transplant Mortality with High Precision

By MedXY 02/21/2026

Researchers have developed the Liver Immune Frailty Index (LIFI), a biomarker-based tool using fractalkine and MMP3 to predict post-liver transplant mortality. With a C-statistic of 0.83, LIFI identifies high-risk candidates, potentially transforming preoperative risk stratification and perioperative management.

news Psychiatry

Rest-Activity Rhythms as Digital Biomarkers: Predicting Relapse in Major Depressive Disorder via Actigraphy

By MedXY 02/21/2026

A landmark one-year actigraphy study reveals that sleep phase variability and daily activity amplitude are significant objective markers for predicting MDD relapse, offering a scalable path toward personalized, preventive psychiatric care.

Cardiology Emergency Medicine news

Novel Handheld Assist Device Quadruples Success Rates of Valsalva Maneuver in Supraventricular Tachycardia

By MedXY 02/21/2026

A randomized clinical trial demonstrates that a handheld Valsalva assist device significantly improves sinus rhythm restoration in SVT patients compared to the standard maneuver, achieving a 63.2% success rate versus 29.2% in a clinical setting.

Cardiology news

Is Prasugrel the New Gold Standard? Ticagrelor Fails Noninferiority in High-Risk Diabetic and STEMI Populations

By MedXY 02/20/2026

Recent data from the TUXEDO-2 and ISAR-REACT 5 trials suggest prasugrel may provide superior outcomes over ticagrelor in high-risk PCI patients, including those with diabetes and STEMI.

news Oncology Otorhinolaryngology

Optimizing Prognosis: The New AJCC Version 9 Staging for Salivary Gland Carcinoma

By MedXY 02/20/2026

The proposed AJCC/UICC Version 9 staging for salivary gland carcinoma shifts toward a unified, specific system using lymph node count and extranodal extension, significantly improving prognostic accuracy for both major and minor salivary gland malignancies.

AI news Oncology Pathology & Lab Medicine

Precision Oncology Meets Artificial Intelligence: Navigating Ancestry-Associated Variability in Digital Pathology for EGFR Prediction

By MedXY 02/20/2026

This review evaluates the generalizability of AI pathology models in predicting EGFR mutations, highlighting significant performance variations across genetic ancestries and specimen types, and their role in clinical triage.

news Oncology Urology

Salvage Focal Therapy vs. Radical Prostatectomy: Comparable 10-Year Survival with Dramatically Reduced Morbidity

By MedXY 02/20/2026

A landmark multicenter study indicates that salvage focal therapy (sFT) achieves long-term cancer-specific survival comparable to salvage radical prostatectomy (sRP) while significantly lowering the risk of major perioperative complications for patients with localized radiorecurrent prostate cancer.

Neurology news

Sex-Specific P-Tau217 Dynamics: Why Women Exhibit Accelerated Tau Accumulation and Cognitive Decline

By MedXY 02/20/2026

A multi-cohort study demonstrates that women with amyloid-β pathology show higher plasma p-tau217 levels and faster tau PET accumulation than men, providing a biological basis for their increased risk of rapid cognitive decline in preclinical Alzheimer’s disease.

Cardiology news Pediatrics

Early Selective Ibuprofen for Patent Ductus Arteriosus Fails to Improve Outcomes in Extremely Preterm Infants: Insights from the Baby-OSCAR Trial

By MedXY 02/20/2026

The Baby-OSCAR trial demonstrates that early selective treatment of large patent ductus arteriosus with ibuprofen in extremely preterm infants does not significantly reduce death or bronchopulmonary dysplasia, nor does it improve neurodevelopmental outcomes at two years.

Cardiology news Pediatrics

Prophylactic Acetaminophen Fails to Improve Intact Survival in Preterm Infants: Lessons from the TREOCAPA Trial

By MedXY 02/20/2026

The TREOCAPA randomized clinical trial demonstrates that while prophylactic intravenous acetaminophen effectively promotes patent ductus arteriosus closure in extremely preterm infants, it does not significantly increase survival without severe neonatal morbidities at 36 weeks' postmenstrual age.

Diabetes & Endocrinology Internal Medicine news

Produce Prescriptions Alone Fail to Improve Diabetes Outcomes: Lessons from a Major Pragmatic Trial

By MedXY 02/20/2026

A large-scale randomized trial reveals that monthly produce subsidies do not significantly improve HbA1c or reduce healthcare utilization in food-insecure diabetes patients, suggesting that 'Food is Medicine' initiatives require more than just financial assistance.

Cardiology Critical Care news

Redefining Post-Cardiac Arrest Care: Two-Year TTM2 Data Confirm No Long-Term Advantage for Targeted Hypothermia

By MedXY 02/20/2026

This 2-year follow-up of the TTM2 trial demonstrates that targeted hypothermia at 33°C provides no long-term benefit for functional or cognitive recovery compared to targeted normothermia. The findings emphasize the importance of early fever management and suggest a recovery plateau after six months post-arrest.